JP2008005702A - Bacillus macroides bacterium and food using the same - Google Patents

Bacillus macroides bacterium and food using the same Download PDF

Info

Publication number
JP2008005702A
JP2008005702A JP2004353360A JP2004353360A JP2008005702A JP 2008005702 A JP2008005702 A JP 2008005702A JP 2004353360 A JP2004353360 A JP 2004353360A JP 2004353360 A JP2004353360 A JP 2004353360A JP 2008005702 A JP2008005702 A JP 2008005702A
Authority
JP
Japan
Prior art keywords
strain
bacillus
nite
macroides
spores
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004353360A
Other languages
Japanese (ja)
Inventor
Mikio Yamori
幹男 矢守
Masahiro Inoue
雅広 井上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXCEL JAPAN CO Ltd
Original Assignee
EXCEL JAPAN CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EXCEL JAPAN CO Ltd filed Critical EXCEL JAPAN CO Ltd
Priority to JP2004353360A priority Critical patent/JP2008005702A/en
Priority to PCT/JP2005/022388 priority patent/WO2006062104A1/en
Publication of JP2008005702A publication Critical patent/JP2008005702A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/742Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07Bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To find a component most contributing to the prevention and treatment of diseases, the prevention of aging, the enhancement in the immunizing power and so on, and to provide a novel health food or beverage using this component. <P>SOLUTION: The present invention provides Bacillus macroides Excel 001 (NITE BP-29) strain which forms whitish brown colonies with irregularly shaped edges on the LB (Luria-Bertani) agar medium and spores of this strain formed in the conditions with insufficient nourishment. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は、バチルス・マクロイデス(Bacillus macroides)菌及びそれを利用した食品に関する。さらに詳しくは、病気予防や老化防止、免疫力向上等を目的とする健康食品として利用し得る、バチルス・マクロイデス菌の技術分野に属する。   The present invention relates to Bacillus macroides bacteria and foods using the same. More specifically, it belongs to the technical field of Bacillus macroides, which can be used as a health food for the purpose of disease prevention, aging prevention, immunity improvement and the like.

従来、病気予防や老化防止、免疫力向上等を目的として、種々の健康食品・飲料が提案されている。
例えば、(特許文献1)には、アガリクス・ブラゼイ・ムリル(Agaricus blazei murill)菌糸体エキスの製造方法が開示されている。具体的な製造の手順は、請求項1に例として示すように、下記の各段階、すなわち(a)水をベースとする培養液を使用し、アガリクス・ブラゼイ・ムリルの菌糸体を培養可能な培地上で培養液1リットルあたり30〜150gのアガリクス菌糸体を0〜25℃で少なくとも1週間培養する段階、(b)1〜10気圧の圧力で1〜4日間かけて液温を少なくとも30℃に上げてアガリクス・ブラゼイ・ムリルの菌糸体を上記培地から分離させる段階、(c)段階(b)と同一の条件で曝気を続けながら液温を一気に50℃以上に上昇させて1〜4時間保った後に、常温まで放冷して、この温度で1〜15時間保ち、ついで第1回目のろ過を行う段階、(d)1〜4時間15〜30℃の温度で放置して培養系に存在する雑菌を繁殖させた後、段階(b)と同一の条件で曝気を継続させながら常温で1〜5日間温置してアガリクス・ブラゼイ・ムリルの菌糸体を繁殖させた後に、曝気を中止して12〜36時間保持し、そして段階(b)と同一の条件で曝気をしながら第2回目のろ過を行う段階、(e)段階(b)と同一の条件で曝気を継続しながら常温で2〜7時間温置した後、培養系の液温を少なくとも60℃に上昇させこの温度で30分〜4時間保持して繁殖した雑菌を死滅させ、常温まで放冷してこの温度で1〜6時間温置し、そして最終ろ過を行う段階、(f)培養系を少なくとも1日かけて沸騰させた後に、常温まで放冷してこの温度で1〜6時間温置する段階、(g)上記条件下で曝気を行いながら常温で温置し、この温置の際にアガリクス・ブラゼイ・ムリルの菌糸体の濃度を調整する段階、(h)曝気を中止して温置する段階、及び(i)曝気気圧をできる限り下げて常温で温置する段階、を経ることによって目的のアガリクス・ブラゼイ・ムリルの菌糸体エキスを得ることができる、とされている。
Conventionally, various health foods and beverages have been proposed for the purpose of disease prevention, aging prevention, immunity improvement and the like.
For example, (Patent Document 1) discloses a method for producing an agaricus blazei murrill mycelium extract. Specifically, as shown in the example of claim 1, the specific production procedure is as follows. (A) Using a culture medium based on water, the mycelium of Agaricus blazei muryl can be cultured. Culturing 30 to 150 g of Agaricus mycelium per liter of culture medium on a medium at 0 to 25 ° C. for at least 1 week, (b) at least 30 ° C. over 1 to 4 days at a pressure of 1 to 10 atm. Separating the mycelium of Agaricus blazei murrill from the above medium, and (c) raising the liquid temperature to 50 ° C. or more at a stretch while continuing aeration under the same conditions as in step (b) for 1 to 4 hours After being kept, it is allowed to cool to room temperature, kept at this temperature for 1 to 15 hours, and then subjected to the first filtration, (d) left at a temperature of 15 to 30 ° C. for 1 to 4 hours to form a culture system After breeding existing bacteria, Incubate for 1 to 5 days at room temperature while continuing aeration under the same conditions as in (b) to propagate the mycelium of Agaricus blazei and Muryl, stop aeration and hold for 12 to 36 hours, and The step of performing the second filtration while aeration is performed under the same conditions as in step (b), (e) after incubating at room temperature for 2 to 7 hours while continuing the aeration under the same conditions as in step (b), The temperature of the culture system is raised to at least 60 ° C. and maintained at this temperature for 30 minutes to 4 hours to kill the propagated germs, allowed to cool to room temperature, incubated at this temperature for 1 to 6 hours, and final filtration (F) boiling the culture system for at least one day, allowing it to cool to room temperature, and incubating at this temperature for 1 to 6 hours, (g) room temperature while performing aeration under the above conditions Incubate with agaricus, brazei and murrill mycelium The target agaricus brazei muryl hyphae through a step of adjusting the concentration, (h) a stage of stopping aeration and incubating, and (i) a stage of lowering the aeration pressure as much as possible and incubating at room temperature It is said that body extract can be obtained.

上記エキスは現在、商品名「大和神茸」として、農事組合法人 大和新茸生産組合により製造販売されており、実際に、ガン、肝臓疾患、糖尿病等の数々の病気に対する予防・治療効果を有することが報告され、好評を博している。
しかしながら、病気の予防・治療、老化防止、あるいは免疫力の向上等に対して、「大和神茸」中のどのような成分が最も作用しているのか、またその成分と病気の予防・治療効果等との因果関係については未だ明確にはされていなかった。
The above-mentioned extract is currently manufactured and sold under the trade name “Yamato Shinto” by the agricultural union corporation Yamato Shingo Production Association, and actually has preventive and therapeutic effects on a number of diseases such as cancer, liver disease and diabetes. It has been reported and has been well received.
However, what ingredients in “Yamato Shrine” are most effective in preventing and treating diseases, preventing aging, improving immunity, etc., and the ingredients and disease prevention and treatment effects The cause-and-effect relationship with the others has not been clarified yet.

特許第2887756号公報Japanese Patent No. 2887756

そこで本発明は、上記従来の状況に鑑み、「大和神茸」を分析することによって病気の予防・治療、老化防止、あるいは免疫力の向上等に最も寄与している成分を見出すとともに、その成分を利用した新規な健康食品・飲料を提供することを目的とする。   Therefore, in view of the above-described conventional situation, the present invention finds a component that contributes most to prevention / treatment of diseases, prevention of aging, improvement of immunity, etc. by analyzing “Yamato Shrine” and its components. The purpose is to provide new health foods and beverages that use food.

上記課題を解決するため、本発明者が鋭意研究を行った結果、「大和神茸」の培養物中に、いずれのバッチにも同一の白褐色コロニーを見出した。このコロニーは、rRNA遺伝子の塩基配列からバチルス・マクロイデス(Bacillus macroides)と同定され、これにより本発明を完成するに至った。すなわち本発明は、以下の(1)〜(4)から構成されるものである。   In order to solve the above problems, the present inventor conducted intensive studies, and as a result, the same white-brown colony was found in all batches in the culture of “Yamato Shrine”. This colony was identified as Bacillus macroides from the base sequence of the rRNA gene, thereby completing the present invention. That is, this invention is comprised from the following (1)-(4).

(1)LB(Luria−Bertani)寒天培地上で辺縁不整形な白褐色コロニーを形成する、バチルス・マクロイデス(Bacillus macroides)Excel001(NITE P−29)菌株。
(2)16SrRNA遺伝子が配列番号1に示す塩基配列を有する、バチルス・マクロイデス(Bacillus macroides)Excel001(NITE P−29)菌株。
(3)さらに栄養源の欠乏状態におくことで芽胞化させたことを特徴とする上記(1)又は(2)記載のバチルス・マクロイデス(Bacillus macroides)Excel001(NITE P−29)菌株。
(4)上記(1)〜(3)のいずれか記載のバチルス・マクロイデス菌株の培養物を含むことを特徴とする食品。
(1) A Bacillus macroides Excel001 (NITE P-29) strain that forms white-brown colonies with irregular edges on an LB (Luria-Bertani) agar medium.
(2) A Bacillus macroides Excel001 (NITE P-29) strain in which the 16S rRNA gene has the base sequence shown in SEQ ID NO: 1.
(3) The Bacillus macroides Excell001 (NITE P-29) strain described in (1) or (2) above, which is further spored by being in a nutrient-deficient state.
(4) A food comprising a culture of the Bacillus macroides strain according to any one of (1) to (3) above.

本発明に係るバチルス・マクロイデス菌を利用することにより、病気の予防・治療作用、老化防止作用、あるいは免疫力向上作用等の特長を有する健康食品・飲料を得ることができる。
さらに、上記バチルス・マクロイデス菌は、栄養源の欠乏状態におき芽胞化させることで、その効果をより高めることができる。この理由は定かではないが、芽胞化により消化酵素の影響を受けずに腸管まで達しそこで発芽することで、腸管免疫に影響を与えるためではないかと推測される。
By using the Bacillus macroeides according to the present invention, it is possible to obtain a health food / beverage having features such as disease prevention / treatment action, anti-aging action, or immunity improvement action.
Furthermore, the effect of the Bacillus macroeidobacterium can be further enhanced by allowing the Bacillus macroeides to sprout in a nutrient-deficient state. The reason for this is not clear, but it is presumed that spore formation may affect the intestinal immunity by reaching the intestinal tract without being affected by digestive enzymes and sprouting there.

以下、本発明の実施の形態について詳細に説明する。
本発明に係る菌株は、アガリクス系の菌糸体エキスとして製造販売されている「大和神茸」の分析を契機として見出されたものである。
Hereinafter, embodiments of the present invention will be described in detail.
The strain according to the present invention has been found on the occasion of analysis of “Yamato Shrine” manufactured and sold as an agaricus mycelium extract.

まず、「大和神茸」を適当な大きさの三角フラスコに入れ、封をして95℃で
5分程度、オートクレーブにより殺菌を行なう。これとは別に、LB寒天培地を入れた殺菌シャーレを調製する。このLB寒天培地上に、オートクレーブ後冷却した大和神茸を置き、37℃の恒温器にて16時間培養した。その結果、いずれのバッチにも共通して辺縁不整形な白褐色コロニーが形成されたため、このコロニーを分離し、以下のように菌の同定を行った。
First, “Yamato Shrine” is placed in an appropriately sized Erlenmeyer flask, sealed, and sterilized by autoclaving at 95 ° C. for about 5 minutes. Separately, a sterile petri dish containing LB agar medium is prepared. On this LB agar medium, Yamato Shrine cooled after autoclaving was placed and cultured for 16 hours in a 37 ° C. incubator. As a result, a white-brown colony with irregular edges was formed in common with all the batches, and this colony was isolated, and the bacteria were identified as follows.

すなわち、単離したコロニーからゲノムDNAを抽出し、抽出したゲノムDNAを鋳型としてPCRにより、16SrRNA遺伝子の約500bpを増幅後、塩基配列を決定した。塩基配列は配列番号1に示す通りである。このrRNA遺伝子のシークエンスは、バチルス・マクロイデス(Bacillus macroides)のrRNA遺伝子と99%以上の相同性を示したため、出願人の名称からBacillus macroides Excel001株と命名し、独立行政法人製品評価技術基盤機構特許微生物寄託センターに2004年10月13日付けで寄託申請し、2004年11月1日に受託番号(NITE P−29)が通知された。   That is, genomic DNA was extracted from the isolated colony, and the base sequence was determined after amplification of about 500 bp of the 16S rRNA gene by PCR using the extracted genomic DNA as a template. The base sequence is as shown in SEQ ID NO: 1. Since this rRNA gene sequence showed 99% or more homology with the Bacillus macroides rRNA gene, it was named Bacillus macroides Excel001 strain from the name of the applicant. A deposit application was filed with the Microorganism Deposit Center on October 13, 2004, and the deposit number (NITE P-29) was notified on November 1, 2004.

上記バチルス・マクロイデス(NITE P−29)菌株は、上述のようにLB寒天培地上で辺縁不整形な白褐色コロニーを形成する。また、長期室温保存にてコロニーの中心部が黒褐色となり、さらにコロニーの周辺部の培地の色が黒褐色化する性質を有している。   The above-mentioned Bacillus macroides (NITE P-29) strain forms white-brown colonies with irregular edges on the LB agar medium as described above. In addition, the central part of the colony becomes dark brown after long-term storage at room temperature, and the color of the medium around the colony becomes dark brown.

この菌株の培養物は、例えば液体中に懸濁させて健康飲料を調整し、適量を摂取することによって病気の予防・治療作用、老化防止作用、免疫力向上等の種々の優れた効能を得ることができる。対象となる疾病は多岐にわたり、例えばガン、肝臓疾患、糖尿病、悪性リンパ腫、バセドー氏病、アトピー性皮膚炎等の皮膚病、インポテンツ、高血圧症等を挙げることができるが、これに限定されるものではない。その作用機序については不明であるが、患者の自己免疫機能に何らかの影響を与えるためと推測される。また、健常人が摂取しても良く、健康維持に有効である。   Cultures of this strain, for example, are suspended in a liquid to prepare a health drink, and by taking an appropriate amount, various excellent effects such as disease prevention / treatment action, anti-aging action, and immunity improvement are obtained. be able to. The target diseases are wide-ranging, and include, for example, cancer, liver disease, diabetes, malignant lymphoma, skin disease such as Basedor's disease, atopic dermatitis, impotence, hypertension, etc. is not. Although its mechanism of action is unknown, it is presumed to have some effect on the patient's autoimmune function. Moreover, it may be taken by healthy people and is effective for maintaining health.

上記バチルス・マクロイデス(NITE P−29)菌株の培養物を含む飲料を調製する場合、その菌の濃度は患者の症状等に応じて適宜設定することができる。一例を示せば、一日あたり1×10〜5×10/ml程度が適当である。また、食品の形態は、飲料だけでなく、ヨーグルト等に添加したり、粉末化された乾燥菌体をそのまま健康食品として用いても良い。また、摂取に便利なように錠剤化してもよい。錠剤化に際しては乳糖などの賦形剤等を適宜用いることができる。 When preparing a beverage containing a culture of the Bacillus macroides (NITE P-29) strain, the concentration of the bacterium can be appropriately set according to the symptoms of the patient. For example, 1 × 10 8 to 5 × 10 8 / ml per day is appropriate. Moreover, the form of food may be added to yogurt or the like as well as beverages, or powdered dry cells may be used as a health food as they are. Alternatively, it may be tableted for convenient consumption. In tableting, excipients such as lactose can be used as appropriate.

さらに、本発明のバチルス・マクロイデス(NITE P−29)菌株は、芽胞化させることによって、食品・飲料として摂取した場合に免疫力向上等の作用がより高まることが分かった。芽胞とは、栄養源の欠乏により、菌体内にコア、コルテックス、スポアコート等の層構造から構成される胞子を形成した状態をいい、熱、乾燥、放射線、酸、アルカリ等に対して強い抵抗性を有する。また、本発明に係る菌株は、芽胞化させた場合に強い休眠状態を保つが、培養条件を整えることにより直ちに発芽して増殖分裂を再開することを確認した。   Furthermore, it has been found that the Bacillus macroides (NITE P-29) strain of the present invention has a spore-forming effect such as an improvement in immunity when ingested as a food / beverage. Spore means a state in which a spore composed of a layer structure such as core, cortex, spore coat, etc. is formed in a microbial cell due to lack of nutrient sources, and is resistant to heat, drying, radiation, acid, alkali, etc. Has resistance. Moreover, although the strain which concerns on this invention maintains a strong dormant state when it makes it spore, it confirmed that it germinated immediately by adjusting culture conditions, and restarted proliferation division.

上述のように、芽胞化によって効果が高まる理由は定かではないが、一つには芽胞化させることで人体に摂取された場合に消化酵素の影響を受けずに腸管まで達し、そこで発芽することができるため、それによって腸管免疫に影響を与え易いためではないかと推測される。   As mentioned above, the reason why the effect is increased by spore formation is not clear, but in one case, when it is ingested by the human body, it reaches the intestinal tract without being affected by digestive enzymes and germinates there. Therefore, it is presumed that this is likely to affect intestinal immunity.

芽胞化させる方法としては、特に限定されるものではなく、バチルス・マクロイデス(NITE P−29)菌株を栄養源の欠乏した適当な培地で培養することにより目的の芽胞を採取することができる。具体的には、例えば、Mgイオン、銅イオン等を含む中性ないしアルカリ性の培地(ニュートリエント培地、酵母エキス・アルブミン培地、ペプトン培地等)を用いて20〜30℃程度で数日間、好気的に培養する方法、1〜5重量%のコーンスティープリカー及び炭素源を含有する培地において、菌株を炭素源が消費し尽くされるまで培養し、その後数十時間通気する方法等を挙げることができる。好気的な培養は、振とう機を用いて振とう培養するか、又はジャーファーメンター等を用いる場合には空気を送り込みながら攪拌することによって行う。   The method for spore formation is not particularly limited, and the target spore can be collected by culturing a Bacillus macroides (NITE P-29) strain in an appropriate medium lacking nutrient sources. Specifically, for example, a neutral or alkaline medium (such as a nutrient medium, yeast extract / albumin medium, or peptone medium) containing Mg ions, copper ions, and the like is aerobic at a temperature of about 20 to 30 ° C. for several days. And a method of culturing the strain until the carbon source is exhausted in a medium containing 1 to 5% by weight of corn steep liquor and a carbon source, and then aeration for several tens of hours. . The aerobic culture is performed by shaking culture using a shaker or by stirring while feeding air when using a jar fermenter or the like.

なお、芽胞化させたバチルス・マクロイデス(NITE P−29)菌株は、芽胞化させない菌株と適宜併用することができる。   The sporulated Bacillus macroides (NITE P-29) strain can be used in combination with a strain that does not sporulate.

(実施例1)バチルス・マクロイデス(NITE P−29)菌株の芽胞を含む飲料の作製
(目的) 低−無栄養の培地である、MCMスタベーションバッファー(MCM starvation buffer)を使用し、バチルス・マクロイデス(NITE P−29)菌株を芽胞化させ、飲料レベルの芽胞水を作製する。
(Example 1) Preparation of beverage containing spores of Bacillus macroides (NITE P-29) (Purpose) A low-nutrient medium, MCM starvation buffer, was used to produce Bacillus macroides. The (NITE P-29) strain is sporulated to produce a beverage level spore water.

(方法) MCMスタベーションバッファー(10mM MOPS、2mM CaCl、4mM MgSO pH7.5(NaOHで調整))を、市販のVolvic water(ミネラルウォーター)を使って作製し、0.25μmのフィルターでろ過した。 (Method) MCM starvation buffer (10 mM MOPS, 2 mM CaCl 2 , 4 mM MgSO 4 pH 7.5 (adjusted with NaOH)) was prepared using a commercially available Volvic water (mineral water), and filtered with a 0.25 μm filter. did.

続いて、50mlのLB培地(Gibco−BRL社製)でバチルス・マクロイデス(NITE P−29)菌株を一晩培養し、3000rpmで10min遠心し、ペレットを作製した。その後、50mlのMCMスタベーションバッファーで2回洗浄し、50mlのMCMスタベーションバッファーに置換した。それを30℃で2日間震盪し、3000rpmで10min遠心後、ペレットを50mlのVolvic waterで3回洗浄し、ペレットを50mlのVolvic waterに置換した。   Subsequently, the Bacillus macroides (NITE P-29) strain was cultured overnight in 50 ml of LB medium (Gibco-BRL), and centrifuged at 3000 rpm for 10 min to prepare a pellet. Then, it was washed twice with 50 ml of MCM starvation buffer and replaced with 50 ml of MCM starvation buffer. It was shaken at 30 ° C. for 2 days, centrifuged at 3000 rpm for 10 min, the pellet was washed 3 times with 50 ml of Volvic water, and the pellet was replaced with 50 ml of Volvic water.

すべての段階を無菌的に行い、三角フラスコなどの容器はすべて市販されている減菌済の容器を使用した。また、洗浄等の各段階で一部のサンプルを回収し、LB培地に播種し、loss等を確認した。   All steps were performed aseptically, and all containers such as Erlenmeyer flasks were sterilized commercially available. Moreover, a part of sample was collect | recovered at each stage, such as washing | cleaning, and it seed | inoculated to LB culture medium and confirmed loss etc.

(結果および考察) 飲料レベルでバチルス・マクロイデス(NITE P−29)菌株の芽胞水の作製を行った。その結果、生菌および芽胞あわせて1.14×10/μlを含む芽胞水を作製することに成功した。芽胞の確認は、95℃、5minの熱処理後、LBプレート上で培養することにより行った。なお、Volvic waterでの洗浄の間に菌(芽胞)を一部喪失していることが明らかとなった。各遠心の段階で保存しておいた上清を、LBプレートに播種して確認した結果、3000rpm×10minの遠心条件では生菌および芽胞を完全にはペレット化できていないことが判明した。遠心の回転数や時間についてはなお改善の余地がある。 (Results and Discussion) Spore water of Bacillus macroides (NITE P-29) strain was prepared at the beverage level. As a result, we succeeded in producing spore water containing 1.14 × 10 4 / μl in total of viable bacteria and spores. Spores were confirmed by culturing on LB plates after heat treatment at 95 ° C. for 5 minutes. In addition, it became clear that some bacteria (spores) were lost during the washing | cleaning by Volvic water. As a result of inoculating the supernatant stored at each centrifugation stage on an LB plate, it was found that viable bacteria and spores could not be completely pelleted under centrifugation conditions of 3000 rpm × 10 min. There is still room for improvement in the number of revolutions and time of centrifugation.

作製した芽胞水を本発明者を含む2名で5mlずつ(5.7×10の生菌および芽胞に相当)試飲したところ、腹痛等は認められず、アトピー性皮膚炎が改善する傾向を示した。 When the prepared spore water was sampled by 5 persons (corresponding to 5.7 × 10 7 viable bacteria and spores) by 2 persons including the present inventor, no abdominal pain was observed, and atopic dermatitis tended to improve. Indicated.

次に、上記芽胞水を希釈して長期に飲用することを考慮し、その際に重要となるVolvic water中での芽胞の長期保存性について調べた。具体的には、芽胞水4、12、31日目の生菌と芽胞の数を検討した。その結果、芽胞水12、31日目においても、それぞれ670/μl、154/μlの芽胞が検出された。確かに芽胞数の減少は認められたが、長期にわたって十分量の芽胞を維持することが明らかとなった。したがって、製品にする際に非常に有利である。   Next, in consideration of diluting the spore water and drinking it for a long time, the long-term storage stability of the spore in Volvic water was examined. Specifically, the number of viable bacteria and spores on the 4th, 12th, and 31st days of spore water was examined. As a result, 670 / μl and 154 / μl of spores were detected on the 12th and 31st days of spores, respectively. Although a decrease in the number of spores was observed, it was revealed that a sufficient amount of spores were maintained over a long period of time. Therefore, it is very advantageous when making a product.

(実施例2)バチルス・マクロイデス(NITE P−29)菌株の芽胞水を作製する際の最適条件の決定
(目的) バチルス・マクロイデス(NITE P−29)菌株の芽胞水を作製する際の最も効率の良い芽胞化条件と芽胞回収方法を検討する。
(Example 2) Determination of optimum conditions for producing spore water of Bacillus macroides (NITE P-29) strain (Purpose) Most efficient in producing spore water of Bacillus macroides (NITE P-29) strain Of good sporulation conditions and spore recovery method.

(方法) 基本的には、上記実施例1と同様にして飲料レベルの芽胞水を作製した。変更点は次の通りである。MCMスタベーションバッファー中で10日間震盪して芽胞の数の変化を調べた。また、Volvic waterで洗浄する際の回転数を10000rpmと15000rpmの2種類で行い、その上清中に残る芽胞の量を調べた。 (Method) Basically, a beverage level spore water was prepared in the same manner as in Example 1. The changes are as follows. The change in the number of spores was examined by shaking in MCM starvation buffer for 10 days. In addition, the number of rotations at the time of washing with Volvic water was 10,000 rpm and 15000 rpm, and the amount of spores remaining in the supernatant was examined.

MCMスタベーションバッファーで10日間震盪後、2000rpm×10minで遠心し、上清を回収した。この上清1mlを10000rpm×10minで遠心し、その上清を100μl回収した。そして、残りの上清およびペレットを再度15000rpm×10minで遠心し、その上清を100μl回収した。残りの上清を全て除き、ペレットを1mlのVolvic waterで再懸濁した。15000rpm×10minで遠心後、上清を除き、再び1mlのVolvic waterで再懸濁する操作を2回繰り返した。最後に、1mlのVolvic waterで懸濁してLBプレートに播種した。   After shaking with MCM starvation buffer for 10 days, the supernatant was collected by centrifugation at 2000 rpm × 10 min. 1 ml of this supernatant was centrifuged at 10,000 rpm × 10 min, and 100 μl of the supernatant was recovered. The remaining supernatant and pellet were centrifuged again at 15000 rpm × 10 min, and 100 μl of the supernatant was recovered. All remaining supernatant was removed and the pellet was resuspended with 1 ml of Volvic water. After centrifugation at 15000 rpm × 10 min, the operation of removing the supernatant and resuspending again with 1 ml of Volvic water was repeated twice. Finally, it was suspended in 1 ml of Volvic water and seeded on an LB plate.

(結果および考察) まず、MCMスタベーションバッファー置換直後の芽胞の数を調べたところ(ネガティブコントロール)、芽胞の形成は認められず、高栄養のLB培地中では芽胞化は起こらないことが分かった。
次に、MCMスタベーションバッファー置換後2、4、6、8、10日目の芽胞の数を測定した。その結果、6日目の芽胞の数が最も多くなり、8日目以降はほとんど芽胞を検出することができなかった。この結果より、MCMスタベーションバッファーでの長期震盪は芽胞数の減少をもたらすことが分かった。
(Results and Discussion) First, when the number of spores immediately after MCM starvation buffer replacement was examined (negative control), no spore formation was observed, and it was found that no spore formation occurred in a high nutrient LB medium. .
Next, the number of spores on the second, fourth, sixth, eighth and tenth days after MCM starvation buffer replacement was measured. As a result, the number of spores on day 6 was the largest, and almost no spores could be detected after day 8. From this result, it was found that long-term shaking with MCM starvation buffer resulted in a decrease in the number of spores.

また、洗浄等の際に芽胞が喪失することが実施例1で明らかになったので、芽胞ペレットを作製する際の最適な遠心条件の決定を行った。その結果、2000rpmでは、ほとんどの芽胞が上清中に残ることが明らかとなった。これを利用して、2000rpmで10min遠心することで、MCMスタベーションバッファー中での生菌や死菌をペレットにして除く(減らす)ことが可能である。   In addition, since it was revealed in Example 1 that spores were lost during washing or the like, optimal centrifugation conditions for producing spore pellets were determined. As a result, it was revealed that most of the spores remained in the supernatant at 2000 rpm. Using this, it is possible to remove (reduce) pellets of live and dead bacteria in the MCM starvation buffer by centrifuging at 2000 rpm for 10 minutes.

Claims (4)

LB寒天培地上で辺縁不整形な白褐色コロニーを形成する、バチルス・マクロイデス(Bacillus macroides)Excel001(NITE P−29)菌株。   A Bacillus macroides Excel001 (NITE P-29) strain that forms white-brown colonies with irregular edges on LB agar. 16SrRNA遺伝子が配列番号1に示す塩基配列を有する、バチルス・マクロイデス(Bacillus macroides)Excel001(NITE P−29)菌株。   The Bacillus macroides Excel001 (NITE P-29) strain, wherein the 16S rRNA gene has the base sequence shown in SEQ ID NO: 1. さらに栄養源の欠乏状態におくことで芽胞化させたことを特徴とする請求項1又は2記載のバチルス・マクロイデス(Bacillus macroides)Excel001(NITE P−29)菌株。   The Bacillus macroides Excell 001 (NITE P-29) strain according to claim 1 or 2, which is further sporulated by being in a nutrient-deficient state. 請求項1〜3のいずれか記載のバチルス・マクロイデス菌株の培養物を含むことを特徴とする食品。
The foodstuff characterized by including the culture | cultivation of the Bacillus macroeides strain in any one of Claims 1-3.
JP2004353360A 2004-12-06 2004-12-06 Bacillus macroides bacterium and food using the same Pending JP2008005702A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2004353360A JP2008005702A (en) 2004-12-06 2004-12-06 Bacillus macroides bacterium and food using the same
PCT/JP2005/022388 WO2006062104A1 (en) 2004-12-06 2005-12-06 Bacillus macroides strain and food using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004353360A JP2008005702A (en) 2004-12-06 2004-12-06 Bacillus macroides bacterium and food using the same

Publications (1)

Publication Number Publication Date
JP2008005702A true JP2008005702A (en) 2008-01-17

Family

ID=36577931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004353360A Pending JP2008005702A (en) 2004-12-06 2004-12-06 Bacillus macroides bacterium and food using the same

Country Status (2)

Country Link
JP (1) JP2008005702A (en)
WO (1) WO2006062104A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013147469A (en) * 2012-01-20 2013-08-01 Calpis Co Ltd Intestinal butyric acid production bacterium increasing agent
CN108587963A (en) * 2018-05-02 2018-09-28 山东农业大学 One plant of Lysinibacillus macroides screened from manioc waste and its application

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060729A1 (en) * 2010-11-03 2012-05-10 Brushkov Anatoly Viktorovich Bacteria strain bacillius sp. - relic microorganisms isolated from permafrost rocks and having immuno-modulating and gero-protective activity
RU2752140C2 (en) * 2019-05-27 2021-07-23 Михаил Вячеславович Аверин Means and method for improving quality of life of mammals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0650981B2 (en) * 1987-09-28 1994-07-06 沢井製薬株式会社 Transformation method using bacterial spores
JP3859254B2 (en) * 1995-12-13 2006-12-20 株式会社応微研 How to grow Agaricus brazii
JP4608059B2 (en) * 2000-08-03 2011-01-05 株式会社エス・ディー・エス バイオテック Protein having insecticidal activity, DNA encoding the protein, pest control agent and control method.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013147469A (en) * 2012-01-20 2013-08-01 Calpis Co Ltd Intestinal butyric acid production bacterium increasing agent
CN108587963A (en) * 2018-05-02 2018-09-28 山东农业大学 One plant of Lysinibacillus macroides screened from manioc waste and its application
CN108587963B (en) * 2018-05-02 2020-07-28 山东农业大学 L ysinibacillus macrocides screened from manioc waste and application thereof

Also Published As

Publication number Publication date
WO2006062104A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
CN1094972C (en) Lactobacillus strains of human origin, their compositions and uses thereof
JP4519202B2 (en) New fermented milk and its use
CN104845912A (en) Lactobacillus plantarum
CN1701116A (en) Probiotic bacterium: lactobacillus fermentum
JP5218041B2 (en) Rice lactic acid fermented food and drink and method for producing the same
JP4456160B2 (en) Novel lactic acid strains and their use
CN100406552C (en) One strain forming a block type fanjun fungus, fermentation culturing method and application thereof
JP4465337B2 (en) Strain producing a large amount of an inhibitor of α-glucosidase and method for producing the same
CN107201315A (en) A kind of Paecilomyces thermaphila mutagenic strain and its method of mutagenesis and application
CN113789294A (en) Method for improving adhesion capacity of lactobacillus fermentum DALI02
CN106497982B (en) A kind of alpha-glucosidase restrainer and preparation method thereof
CN113789280B (en) Lysine bacillus fusiformis preparation for degrading uric acid and preparation method and application thereof
JP2018525988A (en) Bacillus subtilis strain with high production of thrombolytic enzymes
WO2006062104A1 (en) Bacillus macroides strain and food using the same
CN113249244A (en) Lactobacillus paracasei for antagonizing pharyngitis pathogenic bacteria beta hemolytic streptococcus
CN110272850B (en) New strain with algae dissolving capacity and application thereof to phaeocystis globosa
JP2019517810A (en) Bacillus licheniformis NY1505 strain producing a large amount of α-glucosidase inhibitor
CN113755377B (en) Paramycosis bacillus preparation for degrading uric acid and preparation method and application thereof
CN1274809C (en) Bifidobacterium longum
CN113956993B (en) Lactobacillus paracasei with effect of relieving oxidative damage of human keratinocytes
CN115637240A (en) Bacillus belgii and application thereof
CN102399728B (en) Lactobacillus and fermentation method thereof
CN113061550B (en) Lactobacillus new strain Z6 and application thereof in food
CN107760724A (en) A kind of method and the α glucosidase inhibitors that α glucosidase inhibitors are prepared using Paenibacillus polymyxa
CN1986775A (en) Bacillus subtilis strain suitable for light fermented soybean pure-breed fermentation